Seeking Alpha
11 Nov 2026, 21:39 UTC · 1h ago
PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes
Impact · against what's priced in
PepGen's stock has already reacted aggressively to the positive Phase 2 DM1 data, meaning the efficacy results are now baked into the price. The ongoing U.S. clinical hold and the risks associated with the small sample size remain the primary headwinds for the valuation.
- PEPG+0.10
No priced-in read yet
- In context
While the 46.5% splicing correction is positive, the stock's 100% surge indicates the market has already priced in this efficacy. The remaining catalyst is the 12.5 mg/kg cohort data and the lifting of the U.S. clinical hold.
Read from the article alone
Top 1 mover · tap to explore
